Navigation Links
Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 September 2009
Date:11/11/2009

licensure of the current liquid-frozen formulation, but represents an additional business opportunity of major strategic importance. The company expects that the prospective contract will constitute the gateway towards securing additional contracts with the US Government and outside the US as well.

Further detailed PROSTVAC(TM) data presented at the ECCO 15 - 34th ESMO Congress

Further data from the Phase II study with PROSTVAC(TM) were presented at the European CanCer Organisation (ECCO), ECCO 15 - 34th ESMO Congress in Berlin in September. The data indicate the potential for a broader therapeutic use of PROSTVAC(TM) in metastatic prostate cancer

Important events after the period

Delivery of IMVAMUNE(R) to Canada completed

As planned, Bavarian Nordic has delivered 20,000 doses of IMVAMUNE(R) to the Canadian government. A pre-New Drug Submission (NDS) meeting with Health Canada (National Regulatory Authority) was held in October 2009 to discuss the potential to file an NDS in 2010 for IMVAMUNE(R) as a safer smallpox vaccine under a Notice of Compliance with Conditions (NOC/C). Conclusions from the meeting have not yet been finalised.

Encouraging data for MVA-BN(R) HIV multiantigen warrant further studies

Bavarian Nordic has completed the analysis of the Phase I/II studies with MVA-BN(R) HIV multiantigen. The final safety and immunogenicity data demonstrate that the vaccine induces a broad T cell response in HIV infected subjects. The high number of responders to the vaccine is encouraging and warrant further studies. Thus, in line with its strategy, Bavarian Nordic is now looking for a partner in order to secure the continued development of MVA-BN(R) HIV multiantigen in a full Phase II.

Bavarian Nordic acquires remaining shares in its subsidiary BN ImmunoTherapeutics Inc. and subsequently own 100% of the subsidiary

Bavarian Nordic has entered into a conditiona
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Bavarian Nordic Has Signed Contract With an EU Country for the Delivery of IMVAMUNE(R)
2. Bavarian Nordic A/S - Half Year Interim Report 2009
3. Bavarian Nordic in Negotiations With the US Authorities for the Further Development of IMVAMUNE(R)
4. The Court Supports Bavarian Nordics Decision to Start Patent Infringement Case Against Oxford BioMedica
5. Bavarian Nordic Announces its Interim Report for the Period 1 January to 31 March 2009
6. Bavarian Nordic Publishes its Annual Results 2008
7. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
8. Bavarian Nordics Case Against Oxford BioMedica
9. Bavarian Nordic Receives USD 25 Million Milestone Payment After Submission of Important IMVAMUNE(R) Data to The U.S. Health Authorities
10. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
11. Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 27, 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... regenerative medicine, today announced that executives from the company ... of September.  , Pedro Lichtinger ... Renshaw,s 17th Annual Global Investment Conference on Wednesday, September ... Regis Hotel in New York City ...
(Date:8/27/2015)... Aug. 27, 2015 HUYA Bioscience International (HUYA) today ... the Japan Society of HTLV-1, held this week at ... purpose of the Society is to promote research on ... of medical technology and research related to these fields ... "HUYA is proud to support this prestigious conference," ...
(Date:8/27/2015)... MA (PRWEB) , ... August 27, 2015 , ... Inc. ... United States, ranking iLab Solutions as number 1,361 in growth for the three years ... of the top 0.1% fastest-growing privately held organizations in the country. , “We ...
(Date:8/27/2015)... N.C. , Aug. 27, 2015 ... decision by FedEx, UPS and The US Postal ... biological specimens classified as ,select agents, by the ... history of handling these sensitive shipments. ... global transportation regulations, trained and certified personnel to ...
Breaking Biology Technology:Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3Marken Ensures Safe Transportation Of Select Agents And Toxins 2
... Cell Through In Vivo ... Imaging-, ... ) today introduced Bioware(R) Ultra cell lines,a range of ultra bright light ... cell lines are,10 to 100 times brighter than cell lines created using ...
... Oncolytics Biotech Inc.,(TSX: ONC, NASDAQ: ONCY) announced that ... Nemours Center for Childhood Cancer Research entitled,"Radiation in ... at the American Association for Cancer Research (AACR),Annual ... Diego, California from,April 12-16, 2008., "The combination ...
... Sign Manufacturing and Distribution Agreement, GURGAON, ... Ranbaxy,Pharmaceuticals Inc. (RPI), a wholly owned subsidiary ... it has reached several,agreements with AstraZeneca. Two ... third agreement pertains to Omeprazole 40mg,tablets, and ...
Cached Biology Technology:Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines 2Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines 3Oncolytics Biotech Inc. Collaborators Present Reovirus Research for Pediatric Sarcomas at AACR Annual Meeting 2Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation 2Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation 3
(Date:8/12/2015)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is proud to announce that iMedNet ... technology platform, has led the way to significant and ... 2015.   Q2 2015 and Q1 2015 were, respectively, ... value sold in the company,s 15 year history.  In ...
(Date:8/10/2015)... and TELTOW, Germany , ... Instruments (SMI), a world leader in Eye Tracking ... completion of its OEM Eye Tracking Platform for integration ... Tracking Platform contains reference designs for seamless integration of ... systems, virtual reality HMDs and augmented reality smart glasses. ...
(Date:8/5/2015)... , August 5, 2015 ... & Access Management Market by Software, Services, Vertical (BFSI, Airport, ... & Geography - Global Forecast to 2020", published by ... Management Market globally into various segments. The global PIAM ... 2014 to $546.2 Million by 2019, at a CAGR ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... its damaging effect on the environment and its illegal ... to adverse effects on human health, such as inflammation ... damage and possibly cancer. In a ... journal Environmental Research Letters, researchers took air ...
... pinpoint a small RNA that spurs cells to manufacture a ... Alzheimer,s disease (AD) or other types of neurodegeneration. The study ... of Cell Biology ( www.jcb.org ). Like ... in more than one version. Although scientists have identified numerous ...
... Nature a new molecular pathway used to suppress blood ... potential therapeutic value for fighting diseases of the retina and ... blood cells involved in the immune system, use this molecular ... in the same study researchers were able to reverse this ...
Cached Biology News:'E-waste pollution' a threat to human health, new research suggests 2Novel pathway regulating angiogenesis may fight retinal disease, cancers 2
... MAX POWER 500V Programmable Power Supply ... which can handle virtually any application ... current blotting. It is unique in ... The MAX POWER Programmable Power Supply ...
Coating : Poly-D-Lysine ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vol working : 2.5-3.0 ml ...
BD BioCoat Collagen IV 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse collagen type IV....
BD BioCoat Matrigel Matrix 35 mm Culture Dishes Coating : BD MatrigelTM Basement Membrane Matrix ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vo...
Biology Products: